Methylphenidates
18 PRODUCTS · CLASS OVERVIEW
Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy
Overview
- Active ingredients: dexmethylphenidate hydrochloride; methylphenidate; methylphenidate hydrochloride; serdexmethylphenidate and dexmethylphenidate.
- DEA schedule: Schedule II controlled substance (CII) (all 18 products).
- Generic available: 11 of 18 (see the table; status from each product’s Orange Book data).
- Forms: Capsule; Chewable tablet (immediate release); Delayed-release and extended-release capsule; Extended-release capsule (bimodal bead); Extended-release capsule (biphasic bead); Extended-release capsule (multilayer bead); Extended-release chewable tablet; Extended-release oral suspension; Extended-release orally disintegrating tablet; Extended-release tablet; Extended-release tablet (OROS); Immediate-release tablet; Oral solution; Transdermal system.
- Status notes: Ritalin LA: sources differ on brand status; Aptensio XR: sources differ on brand status; Daytrana: sources differ on brand status; Adhansia XR: discontinued; Metadate CD: Aytu brand discontinued · now Lannett; Methylphenidate ER (10/20 mg): Ritalin-SR brand discontinued; Methylphenidate Chewable: Methylin chewable brand discontinued.
How it works
Methylphenidate blocks the transporters that normally remove dopamine and norepinephrine from the synapse. This increases the amount of these neurotransmitters available to act on receptors, particularly in brain areas involved in attention and impulse control.
Mechanism summary reused from the Ritalin page (mechanism per its Prescribing Information, revised 02/2025).
Products
Formulation, duration and approved ages as stated on each product page (from its label). Generic: “Yes” means an FDA-approved generic or authorized generic is available.
| Product | Formulation | Duration | Approved ages | Generic |
|---|---|---|---|---|
| Concerta | Extended-release tablet (OROS) | About 10–12 hours after a morning dose; benefit lasted through 12 hours in the label’s studies in children. | 6 to 65 years (FDA label) | Yes |
| Focalin XR | Extended-release capsule (bimodal bead) | Benefit at every time point measured through 12 hours in children’s classroom studies. | 6 years and older, including adults (not recommended under 6) | Yes |
| Jornay PM | Delayed-release and extended-release capsule | Taken in the evening; improvement from 9 a.m. through 7 p.m. the next day in the main children’s study. | 6 years and older | No |
| Ritalin LA sources differ on brand status | Extended-release capsule (bimodal bead) | Usually about 8 hours after a morning dose; the label gives no fixed duration. | Children 6 to 12 years (FDA label); not recommended under 6 | Yes |
| Aptensio XR sources differ on brand status | Extended-release capsule (multilayer bead) | Benefit at every time point from 1 to 12 hours in a children’s classroom study. | 6 years and older | Generic approved · on back order |
| Quillivant XR | Extended-release oral suspension | Benefit from 45 minutes through 12 hours in a children’s classroom study. | 6 years and older | Generic approved · sources differ |
| Cotempla XR-ODT | Extended-release orally disintegrating tablet | Benefit at time points from 1 to 12 hours in a children’s classroom study. | 6 to 17 years | Yes |
| Azstarys | Capsule | Effects were assessed from 30 minutes to 13 hours after the dose in the classroom study. | 6 years and older | No |
| Daytrana sources differ on brand status | Transdermal system | Patch worn up to 9 hours; benefit from 2 through 12 hours after application in studies. | 6 to 17 years | Yes |
| Ritalin | Immediate-release tablet | Each dose usually helps for about 3–4 hours; the label gives no exact duration. | ADHD in children 6 years and older and adults; narcolepsy | Yes |
| Adhansia XR discontinued | Extended-release capsule (multilayer bead) | In studies, benefit through 13 hours in children and up to 16 hours in adults. | 6 years and older | No |
| QuilliChew ER | Extended-release chewable tablet | Benefit at 45 minutes and at 2, 4 and 8 hours in a children’s classroom study. | 6 years and older | No |
| Focalin | Immediate-release tablet | Each dose is commonly described as lasting about 4 hours; the label gives no fixed duration. | — | Yes |
| Relexxii | Extended-release tablet | Benefit maintained through 12 hours in the studies supporting its approval. | 6 to 65 years | No TE-rated generic |
| Metadate CD Aytu brand discontinued · now Lannett | Extended-release capsule (biphasic bead) | Usually about 8 hours (roughly a school day); the label gives no fixed duration. | 6 years and older, children and adolescents (FDA label; not indicated for adults) | Yes |
| Methylin | Oral solution | Each dose usually helps for about 3–4 hours; the label gives no exact duration. | ADHD in children 6 years and older and adults; narcolepsy | Yes |
| Methylphenidate ER (10/20 mg) Ritalin-SR brand discontinued | Extended-release tablet | About 8 hours (label duration of action). | ADHD in children 6 years and older and adults; narcolepsy | Yes |
| Methylphenidate Chewable Methylin chewable brand discontinued | Chewable tablet (immediate release) | Each dose usually helps for about 3–4 hours; the label gives no exact duration. | ADHD in patients 6 years and older; narcolepsy | Yes |
Comparisons and guides
- Concerta vs Ritalin LA
- Concerta vs Vyvanse
- Focalin XR vs Concerta
- Ritalin vs Adderall
- Stimulants vs Nonstimulants
- All comparisons · Switching guide · Availability tracker · Label update log
Sources
Each product’s current prescribing information, as cited on its page (other sources are listed on each product page):
- Janssen Pharmaceuticals, Inc. Concerta (methylphenidate HCl) Extended-Release Tablets Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
- Sandoz Inc. Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Ironshore Pharmaceuticals Inc. (manufactured for Collegium Pharmaceutical, Inc.). Jornay PM (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Novartis Pharmaceuticals Corporation. Ritalin LA (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025. FDA label (NDA 021284); DailyMed (accessed Oct 2026).
- Rhodes Pharmaceuticals L.P. Aptensio XR (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 09/2025; SPL marketing end dates. DailyMed (accessed Oct 2026).
- Tris Pharma, Inc. (SPL labeler NextWave Pharmaceuticals, Inc.). Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII. Prescribing Information, revised 03/2026. DailyMed (accessed Oct 2026).
- Neos Therapeutics Brands, LLC. Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Corium, LLC (SPL labeler Commave Sub, LLC). Azstarys (serdexmethylphenidate and dexmethylphenidate) capsules, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Noven Therapeutics, LLC. Daytrana (methylphenidate transdermal system), CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Sandoz Inc. Ritalin (methylphenidate hydrochloride) tablets, CII. Prescribing Information, revised 02/2025. DailyMed (accessed Oct 2026).
- Adlon Therapeutics L.P. (Purdue Pharma). Adhansia XR (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information, revised 06/2021; SPL marketing end dates. DailyMed (accessed Oct 2026).
- Tris Pharma, Inc. (SPL labeler NextWave Pharmaceuticals, Inc.). QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets, CII. Prescribing Information, revised 04/2026. DailyMed (accessed Oct 2026).
- Sandoz Inc. Focalin (dexmethylphenidate hydrochloride) tablets, CII. Prescribing Information, revised 05/2024; SPL product data including marketing end dates. DailyMed (accessed Oct 2026).
- Vertical Pharmaceuticals, LLC. Relexxii (methylphenidate hydrochloride) extended-release tablets, CII. Prescribing Information, revised 09/2025. DailyMed (accessed Oct 2026).
- Lannett Company, Inc. Metadate CD (methylphenidate hydrochloride) extended-release capsules, CII. Prescribing Information and Medication Guide, revised 10/2026 (SPL version 4, published Oct 26, 2026). DailyMed (accessed Oct 28, 2026).
- Shionogi Inc. (manufactured by SpecGx LLC). Methylin (methylphenidate hydrochloride) oral solution, CII. Prescribing Information, revised 11/2023. DailyMed (accessed Oct 2026).
- SpecGx LLC. Methylphenidate hydrochloride extended-release tablets, CII (10 mg, 20 mg). Prescribing Information, revised 10/2025. DailyMed (accessed Oct 2026).
- Rising Pharma Holdings, Inc. Methylphenidate hydrochloride chewable tablets, CII (ANDA 205756). Prescribing Information, revised 03/2025. DailyMed (accessed Oct 2026).